Loading clinical trials...

Amodiaquine+Artesunate for Uncomplicated Malaria Treatment | Clinical Trials | Clareo Health

COMPLETEDPHASE4

Amodiaquine+Artesunate for Uncomplicated Malaria Treatment

Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso

NCT01213433•Centre Muraz

Summary

This is a phase IV one-arm study aiming at recruiting 50 patients to assess the efficacy of AQ+AS in patients with a positive RDT diagnosis of malaria in Nanoro, Burkina Faso.

Eligibility

Age

0 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Males and Females aged 6 months and above.
•Body weight of 5 Kg and above.
•RDT positive test.
•Fever (axillary temperature at ≥ 37.5°C) or history of fever in the previous 24 hours.
•Signed (or thumb-printed whenever patients are illiterate) informed consent.
•Patients' willingness and ability to comply with the study protocol for the duration of the study.

Exclusion Criteria

•Participation in any other investigational drug study (antimalarial or others) during the previous 30 days.
•Known hypersensitivity to the study drugs.
•Severe malaria.
•Danger signs: not able to drink or breast-feed, vomiting (\> twice in 24hours), recent history of convulsions (\>1 in 24h), unconscious state, unable to sit or stand.
•Known intercurrent illness or any condition (cardiac, renal, hepatic diseases) which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study.
•Severe malnutrition (defined as weight for height \<70% of the median NCHS/WHO reference).

Locations (1)

CRUN

Nanoro, Boulkiemdé, Burkina Faso

Key Dates

Start Date

October 1, 2010

Primary Completion Date

November 1, 2010

Completion Date

April 1, 2011

Last Updated

July 31, 2015

Enrollment

150

ACTUAL participants

Conditions

Uncomplicated Malaria

Interventions

Artesunate-Amodiaquine

DRUG

Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria

NCT07403643

Uncomplicated Malaria

View study

COMPLETEDPHASE4

Malaria Therapeutic Efficacy Study, Rwanda

NCT04767217

Uncomplicated Malaria

View study

COMPLETEDPHASE2

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 31, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Amodiaquine+Artesunate for Uncomplicated Malaria Treatment

Inclusion Criteria

Exclusion Criteria

Investigating the Pharmacology of Tafenoquine in Papua New Guinean Children With Uncomplicated Malaria

Malaria Therapeutic Efficacy Study, Rwanda

Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmodium Vivax Uncomplicated Treatment in Manokwari, West Papua

Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT)

Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children

Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children